Alnylam

Press Releases

Nov 26,2019
Summary ToggleAlnylam to Webcast Presentations at Upcoming December Investor Conferences
PDF Version
Nov 22,2019
Summary ToggleAlnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day
PDF Version
Nov 20,2019
Summary ToggleAlnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran)
PDF Version
Nov 20,2019
Summary ToggleAlnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)
PDF Version
Nov 19,2019
Summary ToggleAlnylam Announces Second Annual Advocacy for Impact Grants Program
PDF Version
Nov 12,2019
Summary ToggleAlnylam to Webcast Presentation at Stifel 2019 Healthcare Conference
PDF Version
Nov 09,2019
Summary ToggleAlnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
PDF Version
Oct 31,2019
Summary ToggleAlnylam Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Period Activity
PDF Version
Oct 24,2019
Summary ToggleAlnylam Named #1 Biopharma Employer by Science Magazine
PDF Version
Oct 23,2019
Summary ToggleAlnylam to Webcast Conference Call Discussing Third Quarter 2019 Financial Results
PDF Version
Oct 15,2019
Summary ToggleAlnylam’s Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
PDF Version
Oct 10,2019
Summary ToggleAlnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
PDF Version
Sep 26,2019
Summary ToggleAlnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference
PDF Version
Sep 16,2019
Summary ToggleAlnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
PDF Version
Sep 13,2019
Summary ToggleAlnylam Presents New Evidence Demonstrating Significant Association of V122I, a Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, with Clinical Diagnosis of Polyneuropathy
PDF Version
Sep 11,2019
Summary Toggle1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day
PDF Version
Sep 10,2019
Summary ToggleAlnylam Presents New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias
PDF Version
Sep 06,2019
Summary ToggleAlnylam to Host Sixth Annual “RNAi Roundtable” Webcast Series
PDF Version
Sep 03,2019
Summary ToggleAlnylam Presents New Clinical Research Findings at the Second European Meeting of ATTR Amyloidosis for Doctors and Patients
PDF Version
Sep 02,2019
Summary ToggleAlnylam Pharmaceuticals Provides Perspective on Positive Complete Results from ORION-11 Phase 3 Study of Inclisiran
PDF Version
Displaying 1 - 20 of 1055 results
View all releases

Search

: (Common):

Price:
Change (%):
Volume:
Data as of
Copyright NASDAQ. Minimum 15 minutes delay
Learn More